



ASX ANNOUNCEMENT

ANAGENICS LIMITED (ASX: AN1) – DIRECTOR RESIGNATION

SYDNEY, Monday, 17 October 2022:

The Board of Anagenics Limited (ASX: AN1) advises the intention of Mr Dennis Eck to retire as a director following the completion of the Company's 2022 Annual General Meeting.

Mr Eck made a strategic investment in the company in December 2017 and has been a Non-Executive Director at Anagenics since March 2018.

Dennis has been supportive of the continuing restructuring and repositioning of the Business and expresses his intention to continue as a supportive shareholder.

Mr Eck said, "It has been a privilege to collaborate with my fellow Directors and the team at Anagenics. I am about to turn 80 and am simplifying my business associations."

Anagenics Chairman Sandy Beard said "Together with my fellow Directors, I would like to acknowledge and thank Dennis for his significant and lasting contribution to Anagenics and its Board of Directors. His experience and industry insights have been highly insightful to guide the Company's strategy and market development."

The composition of the Board is being considered to ensure an appropriate breadth of capabilities to continue to support the business.

Approved for release by the Board of Directors.

Sandy Beard
Chairman
+61 412 308 263
info@anagenics.com

Anagenics Limited (ASX: AN1)

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. Advangen Pty Ltd is Anagenics' wholly owned subsidiary engaged in the development and sale of proprietary first in class, best in class, clinically validated products for hair, skin and body. For further information, please see www.anagenics.com and www.evolisproducts.com.au.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.